Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Pancreatic Cancer | Correction

Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design

Authors: D. Doppenberg, M. G. Besselink, C. H. J. van Eijck, M. P. W. Intven, B. Groot Koerkamp, G. Kazemier, H. W. M. van Laarhoven, M. Meijerink, I. Q. Molenaar, J. J. M. E. Nuyttens, R. van Os, H. C. van Santvoort, G. van Tienhoven, H. M. Verkooijen, E. Versteijne, J. W. Wilmink, F. J. Lagerwaard, A. M. E. Bruynzeel, for the Dutch Pancreatic Cancer Group

Published in: BMC Cancer | Issue 1/2023

Login to get access

Excerpt

Correction: BMC Cancer 22, 1363 (2022)
Literature
1.
go back to reference Doppenberg D, Besselink MG, van Eijck CHJ, et al. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design. BMC Cancer. 2022;22:1363. https://doi.org/10.1186/s12885-022-10419-4.CrossRef Doppenberg D, Besselink MG, van Eijck CHJ, et al. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design. BMC Cancer. 2022;22:1363. https://​doi.​org/​10.​1186/​s12885-022-10419-4.CrossRef
Metadata
Title
Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
Authors
D. Doppenberg
M. G. Besselink
C. H. J. van Eijck
M. P. W. Intven
B. Groot Koerkamp
G. Kazemier
H. W. M. van Laarhoven
M. Meijerink
I. Q. Molenaar
J. J. M. E. Nuyttens
R. van Os
H. C. van Santvoort
G. van Tienhoven
H. M. Verkooijen
E. Versteijne
J. W. Wilmink
F. J. Lagerwaard
A. M. E. Bruynzeel
for the Dutch Pancreatic Cancer Group
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10521-1

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine